Monday 1 July 2024

The Pharma Letter Podcast — Episode 19 — US midterms and beyond: outlook for pharma

Pharmaceutical
Simon Wentworth
28 November 2022
us-midterms-and-beyond-1

More on this story...

Pharmaceutical
The Pharma Letter Podcast — Episode 17 — Inflation Reduction Act: quick take
17 August 2022
Pharmaceutical
Biden-Harris Administration moves on affordable and accessible healthcare
27 October 2022
Pharmaceutical
Biden names Renee Wegrzyn as first head of ARPA-H
13 September 2022


Related Company News

The Pharma Letter Podcast — Episode 17 — Inflation Reduction Act: quick take
COVID-19 'seems to love' pharma's biggest production centers
First congressional hearing on 'Medicare for all' shows no signs of consensus on controversial issue
More ones to watch >


Today's issue

Pharmaceutical
Boosting crinecerfont, Neurocrine draws from gamut of FDA support
1 July 2024
Biotechnology
Forbion expands to Boston, hires former Dyne CEO
1 July 2024
Pharmaceutical
In ALS, Phase II data show two drugs could be better than one
1 July 2024
Biotechnology
Another win for nipocalimab as J&J closes in on rivals
1 July 2024
Pharmaceutical
Merck & Co sees value in novel prostate cancer drug
1 July 2024
Biotechnology
New Ajovy data challenges treatment breaks in migraine prevention
1 July 2024
Biotechnology
Zenas BioPharma appoints Orlando Oliveira as CCO
1 July 2024

Company Spotlight

A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.




More Features in Pharmaceutical

Boosting crinecerfont, Neurocrine draws from gamut of FDA support
1 July 2024
In ALS, Phase II data show two drugs could be better than one
1 July 2024
Merck & Co sees value in novel prostate cancer drug
1 July 2024
Lonza welcomes new CEO Wolfgang Wienand
1 July 2024


Copyright © The Pharma Letter 2024   |   Headless Content Management with Blaze